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Curcumin blocks homocysteine-induced
endothelial dysfunction in porcine coronary
arteries
Ganesh Ramaswami, MD, PhD, Hong Chai, MD, PhD, Qizhi Yao, MD, PhD, Peter H. Lin, MD, Alan
B. Lumsden, MD, and Changyi Chen, MD, PhD, Houston, Tex
Purpose: Curcumin, a yellow polyphenolic compound from the plant Curcuma ionga, is a commonly used spice and
coloring agent with beneficial effects of anti-tumor, anti-inflammatory, and antioxidant activities. The objective of this
study was to determine the effect of curcumin on homocysteine-induced endothelial dysfunction in a porcine coronary
artery model.
Methods: Porcine coronary arteries were cut into 5-mm rings, which were incubated for 24 hours either as control rings, with
homocysteine (50 mol/L), curcumin (5 mol/L), or a combination of curcumin (5 mol/L) and homocysteine (50
mol/L). Myograph tension analysis was performed in response to vessel active drugs including thromboxane A2 analog
U466419 (contraction), endothelium-dependent vasorelaxation (bradykinin), and endothelium-independent vasorelaxation
(sodium nitroprusside). Immunohistochemical staining was performed for endothelial nitric oxide synthase (eNOS). In
addition, superoxide anion production was determined by lucigenin-enhanced chemiluminescence.
Results:All groups of porcine coronary artery rings showed no difference in maximal contraction after U46619 challenge.
However, endothelium-dependent vasorelaxation in response to 10-5 mol/L bradykinin was 40% in the homocysteine-
treated group, as compared to 73% in the control group (P  .03). Of importance, curcumin could effectively block
homocysteine-induced impairment of endothelium-dependent vasorelaxation. All groups showed no difference in
endothelium-independent vasorelaxation. In addition, eNOS immunoreactivity was reduced in the homocysteine group,
but the combined homocysteine and curcumin group showed eNOS levels comparable to those in the control group.
Furthermore, superoxide anion levels of the endothelial layer were significantly increased by 2-fold in homocysteine-
treated vessels as compared to control vessels (P  .02), whereas curcumin could block the effect of homocysteine on
superoxide anion production.
Conclusion: These data demonstrate that curcumin effectively reverses the endothelial dysfunction induced by homocys-
teine. In addition, curcumin significantly blocked homocysteine-induced superoxide anion production and eNOS
down-regulation. This study suggests a therapeutic role for dietary curcumin in patients with homocysteinemia, thereby
reducing cardiovascular morbidity and mortality. ( J Vasc Surg 2004;40:1216-22.)
Clinical Relevance: Hyperhomocysteinemia is a significant clinical problem. It is an independent risk factor for
cardiovascular diseases. This study provides new information for better understanding the molecular mechanisms of
homocysteine-induced vascular injury. More importantly, curcumin, a natural substance, can effectively block the
detrimental effect of homocysteine on the vascular system. Thus curcumin could be used in patients with hyper-
homocysteinemia, and to prevent cardiovascular diseases.Epidemiologic studies have documented the relation-
ship between risk factors and the development of athero-
sclerotic disease. Traditional risk factors for atherosclerosis
include diabetes, hypertension, hypercholesterolemia, age,
and male gender.1 More recently hyperhomocysteinemia
has emerged as an independent risk factor for development
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1216of coronary, cerebrovascular, and peripheral arterial occlu-
sive disease.2 Although severe hyperhomocysteinemia is
rare, mild elevations in homocysteine concentration have
been found in nearly 7% of the general population and in
20% to 30% of patients with coronary and peripheral vascu-
lar disease.3-5 A mere increase of 12% over the normal level
of homocysteine has been associated with a 3-fold increase
in risk for myocardial infarction.6
Hyperhomocyteinemia exerts its deleterious effect by
causing endothelial injury and dysfunction, followed by
platelet activation and thrombus formation.7 Although
molecular mechanisms of homocysteine-induced vascular
injury are not fully elucidated, increased oxidative stress and
decreased nitric oxide (NO) bioavailability have important
roles in endothelial dysfunction.7,8
Whereas oxidants impair endothelial function, it has
been suggested that the use of antioxidants may reverse
some of the deleterious effects and improve endothelial
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protective effect of dietary antioxidants on the vascular
endothelium.8-10 Curcumin, a polyphenolic compound
obtained from the plant Curcumin ionga, is a commonly
used spice and coloring agent. Several studies have demon-
strated the beneficial effects of curcumin, which include
anti-inflammatory,11 anti-tumor,12 and antioxidant activi-
ty.13 However, curcumin has not been studied in the
vascular system to prevent risk factors such as homocysteine
from vascular injury. Thus the aim of this study was to
determine whether curcumin could effectively reverse ho-
mocysteine-induced endothelial dysfunction, with refer-
ence to endothelium-dependent vasorelaxation, endothe-
lial NO synthase (eNOS) expression, and superoxide anion
production, in porcine coronary arteries. The findings of
this study could suggest a new strategy to prevent or treat
homocysteine-induced vascular disease.
METHODS
Reagents. Thromboxane A2 analog (9,11-dideoxy-
11a,9a-poxymethylprostaglandin F2; U46619), homo-
cysteine (DL-homocysteine dissolved in normal saline solu-
tion), bradykinin, TRIS-buffered saline solution,
phosphate-buffered saline solution (PBS), and curcumin
(water soluble, 95% purity), were obtained from Sigma.
Curcumin (diferuloylmethane), a single chemical com-
pound, is a major constituent of the plantCurcumin ionga.
Dulbecco’s modified Eagle’s medium was obtained from
Life Technologies Inc, and antibiotic-antimycotic from
Mediatech Inc. Monoclonal antibody against human
eNOS was purchased from B. D. Transduction Laborato-
ries. The avidin-biotin complex immunoperoxidase kit was
obtained from DAKO, lucigenin was obtained from Mo-
lecular Probes, and the horseradish peroxidase–conjugated
goat anti-mouse secondary antibodies and the enhanced
chemiluminescence kit were from Amersham Life Sciences.
Isometric tension in porcine coronary arteries. The
myograph system used in this study has been described.8,14
Eight pig hearts were harvested from 8-month-old to 10-
month-old pigs from a local slaughterhouse. The hearts
were then rinsed in cold sterile PBS, the coronary arteries
were then perfused with cold PBS, and the hearts were
placed in cold PBS for transfer back to the laboratory. The
right coronary artery was then carefully dissected out, re-
moving the loose connective tissue, and cut into 5-mm
rings, which were then placed in Dulbecco’s modified
Eagle’s medium as control, with homocysteine (50 mol/
L), curcumin (5 mol/L), or a combination of curcumin
(5mol/L) and homocysteine (50mol/L). A single dose
of curcumin (5mol/L) was selected on the basis of several
previous publications in which the dose showed a potent
inhibitory effect on hypoxia-induced oxidative stress13 or
growth factor–induced cell proliferation15 in human endo-
thelial cells in vitro. The culture medium supplemented
with curcumin (5 mol/L) maintained pH at 7.4. All rings
were incubated at 37°C in a 5% CO2 cell culture incubator.
After 24 hours of incubation, the rings were suspended
between the wires of an organ bath myograph chamber(Danish Myo Technologies) in 6 mL of Kreb’s solution at
37°C and oxygenated with pure oxygen. The rings were
subjected stepwise to a predetermined optimal tension of
3g and allowed to equilibrate for 30 minutes. After equili-
bration, each ring was precontracted with thromboxane A2
analog U46619 (107 mol/L). Endothelium-dependent
vasorelaxation curves were obtained with 5 cumulative
additions of 50 L of endothelium-dependent vasodilator
bradykinin (109, 108, 107, 106, 105 mol/L) at
3-minute intervals. Endothelium-independent vasorelax-
ation was assayed with the addition of a single dose of
sodium nitroprusside (106 mol/L). The percentage relax-
ation was calculated on the basis of tension changes of
precontracted vessel rings. The vessel was precontracted
with U46619 where the tension value was considered as 0%
relaxation. The value of vessel tension before contraction
with U46619 (pretension) was considered 100% relax-
ation. Eight sets of coronary rings were available for each
treatment group, and data obtained from several coronary
arteries were arranged and represented as 1 data point for
statistical analysis.
Immunohistochemistry. The porcine coronary ar-
tery rings were fixed overnight in 10% neutral buffered
formalin, then transferred to 70% alcohol. Dehydration of
the specimen was achieved with sequentially increasing
concentrations of ethanol followed by xylene, and embed-
ded in paraffin. Five-micrometer cross sections were then
cut, stained with hemotoxylin-eosin, and then stained im-
munohistochemically for eNOS with the avidin-biotin
complex immunoperoxidase procedure. Monoclonal anti-
body against human eNOS (1:1000) was used.8
Detection of superoxide. Coronary arteries were iso-
lated from 3 additional pig hearts. Superoxide levels pro-
duced by endothelial cells of the vessel rings were deter-
mined with the lucigenin-enhanced chemiluminescence
method with a Sirius luminometer and FB 12 software
(Berthold Detection System). After 24 hours of culturing,
the rings were rinsed briefly in modified Krebs’ HEPES
(N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid)
buffer solution (120 mmol/L of NaCl, 4.7 mmol/L of
KCl, 1.18 mmol/L of K2HPO4, 20 mmol/L of HEPES,
2.5 mmol/L of CaCl2, 1.17 mmol/L of MgSO4, and 25
mmol/L of NaHCO3). The rings were then cut open
longitudinally into approximately 5  5-mm pieces. Assay
tubes (12  75 mm) were filled with 500 L of Krebs’
HEPES buffer solution and 50 mol/L of lucigenin. The
reagents were gently mixed in the tubes, and the vessel
segments were placed with the endothelium side down.
Measurements were made every 15 seconds for 12minutes.
The data in relative light units per second (RLU/s) for each
sample was averaged between 7 and 10 minutes. Values for
blank tubes containing the same reagents as the vessel ring
samples were subtracted from the corresponding vessel
samples. The area of each vessel segment was measured
with a caliper, and used to normalize the data for each
sample. The final unit is RLU/s/mm2.
Statistical analysis. Differences between the groups
was analyzed with the 2-tailed Student t test for paired data,
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gram). Analysis of variance (ANOVA) was used for com-
parison of vessel response to multiple doses of bradykinin
between treated and control vessels. The results are re-
ported as mean  SE.
RESULTS
Effect of homocysteine and curcumin on vasomotor
function. The maximal vessel tension achieved by the
addition of thromboxane A2 analog U46619 (10
7
mol/L) showed no difference between groups, including
control, homocysteine, curcumin, and homocysteine plus
curcumin (P  .05, Student t test; Fig 1). However,
endothelium-dependent vasorelaxation showed a signifi-
cant difference between groups (Fig 2). In general (Fig 2,
A), homocysteine significantly impaired endothelium-
dependent relaxation in response to multiple doses of bra-
dykinin, as compared with controls (n  8; P  .05,
ANOVA). In response to 105 bradykinin (Fig 2, B) the
relaxation was only 40%  2% in the homocysteine group,
as compared to 72% 2% in the control group (n 8; P
.05, Student t test). Of importance, curcumin had a signif-
icant protective effect on vessel wall injury from homocys-
teine. The rings treated with a combination of homocys-
teine and curcumin showed a significant increase in
vasorelaxation, as compared with homocystein-treated ves-
sels (n 8; P .01, Student t test), which was similar in the
control vessels. In addition, curcumin alone did not affect
vasorelaxation, as compared with the control group. All
groups showed no significant difference in endothelium-
independent relaxation, demonstrated by the addition of a
single dose of sodium nitroprusside (106 mol/L; Fig 3).
Effect of homocysteine and curcumin on eNOS
immunoreactivity. Homocysteine-treated vessels showed
significantly less staining of eNOS protein in comparison
with control vessels. In contrast, the homocysteine plus
Fig 1. Contraction of porcine coronary arteries. Myograph iso-
metric tension apparatus was used to study maximal contraction of
porcine coronary artery rings in response to thromboxane A2
analogU46619 (107 mol/L). There was no significant difference
among control, homocysteine (Hcy), curcumin, and homocysteine
plus curcumin groups (n  8; P  .05, Student t test).curcumin-treated group showed staining levels of eNOSprotein comparable to that in the control group, indicating
the protective effect of curcumin on endothelial cells (Fig
4).
Effect of homocysteine and curcumin on superox-
ide anion production. The effect of curcumin on homo-
cysteine-induced superoxide anion production is shown in
Fig 5. The chemiluminescence of the endothelium showed
that control vessels had superoxide levels of 13  2 RLU/
s/mm2; treatment with homocysteine led to a 2-fold in-
crease in superoxide levels to 40 8 RLU/s/mm2 (n 3;
P  .05, Student t test), whereas the combined homocys-
teine and curcumin group had a reduced level of only 10
Fig 2. Endothelium-dependent vasorelaxation. A, Vasorelax-
ation in response to various doses of bradykinin. B, Vasorelaxation
in response to bradykinin at 105 mol/L. In response to varying
strengths of bradykinin, relaxation of precontracted vessel rings
was measured with a myograph isometric tension apparatus. En-
dothelium-dependent vasorelaxation showed a significant differ-
ence among groups. Homocysteine (Hcy) significantly reduced
bradykinin-induced relaxation in a dose-dependent manner, as
compared with controls (n  8; P  .05, ANOVA test for A,
Student t test for B). Curcumin significantly blocked this effect of
homocysteine. Curcumin alone had no effect on vasorelaxation.1 RLU/s/mm2.
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A major finding of this study was that curcumin effec-
tively reversed the endothelial dysfunction induced by ho-
mocysteine in a porcine coronary artery model. Treatment
of porcine coronary artery rings with 50 mol/L of homo-
cysteine showed a significant reduction of endothelium-
dependent relaxation in response to bradykinin. In addi-
tion, homocysteine reduced eNOS levels and increased
superoxide production. Of importance, the incubation of
the vessel rings with homocysteine plus curcumin effec-
tively reversed the deleterious effects of homocysteine.
Treatment with curcumin restored the endothelium-
dependent relaxation, increased eNOS protein levels, and
decreased superoxide production.
Curcumin, a commonly used spice and coloring agent,
has recently been shown to have a spectrum of beneficial
effects, ranging from anti-inflammatory,11 anti-tumor,12
and antioxidant activity.13 The anti-inflammatory action is
in part due to the free radical scavenging property of
curcumin, which in turn leads to suppression of superoxide
production by macrophages, in addition to countering the
effects of lipopolysaccharide-induced activation of tumor
necrosis factor- and interleukin-1. A recent study showed
that curcumin pretreatment to endotoxemic mice effec-
tively reduced the phagocytic activity of Kupffer cells and
also endothelial swelling.11 It has also been suggested that
the anti-inflammatory action of curcumin may be attribut-
able to inhibition of leukocyte recruitment16 or inhibition
of tumor necrosis factor-–induced expression of adhesion
molecules.17 Curcumin inhibits angiogenic differentiation
of human umbilical vein cells by possible modulation of
protease activity during endothelial morphogenesis.12
Other postulated anti-angiogenic mechanisms of cur-
cumin involve the inhibition of activity of thymidine
kinase enzyme, which effectively blocks cell cycle pro-
gression and up-regulation of cyclin-dependant kinase
inhibitors.15 The protective action of curcumin on the
vascular endothelium against oxidative stress has also
been reported. One study suggested that a possible
mechanism may involve the production of endothelial
heme-oxygenase, an inducible stress protein that de-
grades heme to the vasoactive molecule and the antiox-
idant biliverdin.13 Furthermore, curcumin protects en-
dothelial cells from the oxidative stress induced by
	-amyloid, implicated as a well-established pathway in-
ducing neuronal cell death in Alzheimer’s disease.18
Despite extensive literature on the anti-inflammatory,
anti-tumor, and antioxidant activity of curcumin, we are
not aware of any studies that have documented curcumin
reversal of homocysteine-induced endothelial dysfunction.
Our study showed that curcumin can effectively block
homocysteine-induced decrease in endothelium-depen-
dent vasorelaxation, with a concentration of curcumin as
low as 5 mol/L. This assay was the measure of the vessel
response to bradykinin. It is unlikely that curcumin could
interact with the bradykinin receptor on endothelial cells
because vessels treated with curcumin alone did not affectthe vessel response to bradykinin, as compared with the
control vessels. EC50 for bradykinin is the effective concen-
tration of bradykinin that induces 50%maximum relaxation
and is usually used to express the sensitivity of the tested
vessel to bradykinin.19,20 In our study the maximum relax-
ation among groups was different because of different
treatment conditions. Thus EC50 for bradykinin would not
be a sensitive measure for our data. Rather, the maximun
relaxation in response to bradykinin (105 mol/L) be-
tween groups (Fig 2, B; paired Student t test) or ANOVA
for multiple data points (Fig 2,A) among groups would be
the best methods to present our data. Recent studies have
used curcumin in doses up to 80 mg/kg with no reported
side effects.11 It is possible that curcumin confers its bene-
ficial and protective endothelial effect by decreasing super-
oxide levels. Indeed, our results demonstrate that curcumin
significantly reduced superoxide anion production in por-
cine coronary arteries. This would be similar to the activity
of 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors.21 The results of this study are comparable to those
of a recent study that used a dietary antioxidant, red wine,
to reverse homocysteine-induced endothelial dysfunction
in porcine coronary arteries.8 However, a dose-dependent
study of curcumin or homocysteine is not included in the
study, which could be a limitation. Further investigation of
potential applications of curcumin in vascular systems, in-
cluding a broad dose range, animal models, and human
trials are warranted.
NO produced from eNOS is a known regulator of
vascular tone, blood pressure, and antithrombotic activi-
ty.22-24 Of importance, inadequate NO production and
decreased eNOS expression are seen in atherosclerosis and
other vascular injury.25Homocysteine also increases potent
reactive oxygen free radicals, and this may also explain the
decreased availability of NO, because superoxide anion is
readily reacted with NO to form peroxynitrite anion.26 In
our study homocysteine-treated porcine rings also showed
Fig 3. Endothelium-independent vasorelaxation. In response to
a single dose of sodium nitroprusside (106 mol/L), relaxation of
porcine coronary rings was measured. All groups showed no sig-
nificant difference in endothelium-independent relaxation (n  8;
P  .05, Student t test).a decrease in eNOS immunoreactivity in comparison with
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teine led to eNOS staining levels comparable to control
porcine rings. However, quantitative measurement of the
eNOS expression, including both messenger RNA and
protein levels, was not performed in this study and is
warranted for further investigation.
A single dose of curcumin (5 mol/L) was used in our
in vitro study of porcine coronary arteries. It is not known
whether this concentration is attainable with dietary sup-
plementation in human beings. Curcumin or extract of
Curcumin longa has been used in human trials. However,
the pharmacokinetics of curcumin in human beings is un-
known as yet. Healthy human volunteers received a daily
oral dose of 200 mg of curcumin extract (ZCL4 curcuma)
for 40 or 60 days and demonstrated cardiovascular benefits
such as serum lipid peroxides but absence of any detectable
toxicity.27,28 In other reports individuals who received a
daily oral dose of 1200 to 2500 mg of curcumin for various
periods of time exhibited lack of toxicities.29-33 However,
the plasma level of curcumin was not measured in these
reports. In a clinical pilot study oral doses of 4 to 8 g of
curcumin for 3 months generated plasma levels of 0.51 to
1.77 mol/L.34 However, curcumin concentrations in the
Fig 4. Immunohistochemical staining of endothelial nit
cultured in different groups for 24 hours. eNOS levels we
procedure. Homocysteine (Hcy)–treated vessels showed
vessels. In contrast, the homocysteine plus curcumin
comparable to the control group. A, Control group. B
mol/L) treatment. D, Homocysteine (50 mol/L) pl
400.)tissues, including blood vessels, have not been studied inhuman trials. Thus our in vitro dose of curcumin (5
mol/L) is higher than clinical plasma levels. Effects of a
dose of less than 5 mol/L of curcumin will be interesting
to include in the future investigation of our model system,
to show clinical relevance. In addition, there is no informa-
tion about the effect of curcumin in patients with hyperho-
mocysteinemia. However, curmumin did show antioxidant
effect in human trials.27,28 Inasmuch as a large amount of
data, including those in this study, show that homocysteine
can induce vascular injury through oxidative stress, cur-
cumin could logically be effective to block the detrimental
effects of homocysteine in patients with hyperhomocys-
teinemia. Further clinical investigation is warranted in this
regard.
In summary, homocysteine impairs endothelium-depen-
dent vasorelaxation, decreases eNOS levels, and increases su-
peroxide anion levels, and curcumin can block all of these
effects of homoncysteine in the porcine coronary artery cul-
ture model. The mechanism of the inhibitory effect of cur-
cumin on homocysteine-induced vessel injurymay involve the
antioxidant function of curcumin. Other mechanisms such as
direct interaction between curumin and homocysteine may
ide synthase (eNOS). Porcine coronary artery rings were
ined with the avidin-biotin complex immunoperoxidase
staining of eNOS protein in comparison with control
ed group showed a staining level of eNOS protein
mocysteine (50 mol/L) treatment. C, Curcumin (5
rcumin (5 mol/L) treatment. (Original magnificationric ox
re sta
less
-treat
, Ho
us cuexist and warrant further investigation.
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